Where Gritstone Bio Stands With Analysts
Portfolio Pulse from Benzinga Insights
Gritstone Bio (NASDAQ:GRTS) has received mixed analyst ratings over the past three months, with a recent average price target of $4.0, down from $5.50. Analysts have varied in their ratings, with some maintaining their positions and others lowering their price targets. The company faces significant financial challenges, including a substantial decline in revenue and poor profitability metrics.
August 05, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gritstone Bio has received mixed analyst ratings, with a recent average price target of $4.0, down from $5.50. The company faces significant financial challenges, including a substantial decline in revenue and poor profitability metrics.
The mixed analyst ratings and lowered price targets indicate a lack of confidence in Gritstone Bio's short-term performance. The company's significant financial challenges, including a substantial decline in revenue and poor profitability metrics, further support a negative short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100